Department of Respiratory Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 West Yanjiang Road, Guangzhou, 510120, China.
Cardiovasc Drugs Ther. 2024 Feb;38(1):31-41. doi: 10.1007/s10557-022-07326-y. Epub 2022 Jul 28.
Colchicine, a multipotent anti-inflammatory drug, has been reported to alleviate cardiac remodeling and improve cardiac function after acute myocardial infarction (AMI). However, the underlying mechanism remains incompletely understood. Because neutrophils extracellular traps (NETs) enhance inflammation and participate in myocardial ischemia injury, and colchicine can inhibit NETosis, we thus aimed to determine whether colchicine exerts cardioprotective effects on AMI via suppressing NETs.
Adult C57BL/6 mice were subjected to permanent ligation of the left anterior descending coronary artery and treated with colchicine (0.1 mg/kg/day) or Cl-amidine (10 mg/kg/day) for 7 or 28 days after AMI. Cardiac function was evaluated by echocardiography, and NETs detected by immunofluorescence. ROS production was detected using 2',7'-dichlorodihydrofluorescein diacetates (DCFH-DA) fluorometry. Intracellular Ca concentration was assessed by a fluorometric ratio technique.
We found that colchicine treatment significantly increased mice survival (89.8% in the colchicine group versus 67.9% in control, n = 32 per group; log-rank test, p < 0.05) and improved cardiac function at day 7 (left ventricular ejection fraction (LVEF): 28.0 ± 9.2% versus 12.6 ± 3.9%, n = 8 per group; p < 0.001) and at day 28 (LVEF: 26.2 ± 7.2% versus 14.8 ± 6.7%, n = 8 per group; p < 0.001) post-AMI. In addition, the administration of colchicine inhibited NETs formation and inflammation. Furthermore, colchicine inhibited NETs formation by reducing NOX2/ROS production and Ca influx. Moreover, prevention of NETs formation with Cl-amidine significantly alleviated AMI-induced cardiac remodeling.
Colchicine inhibited NETs and cardiac inflammation, and alleviated cardiac remodeling after acute myocardial infarction.
秋水仙碱是一种多效抗炎药物,据报道可减轻急性心肌梗死(AMI)后的心脏重构并改善心功能。然而,其潜在机制仍不完全清楚。由于中性粒细胞胞外诱捕网(NETs)可增强炎症并参与心肌缺血损伤,并且秋水仙碱可以抑制 NETosis,因此我们旨在确定秋水仙碱是否通过抑制 NETs对 AMI 发挥心脏保护作用。
成年 C57BL/6 小鼠接受左前降支冠状动脉永久性结扎,并在 AMI 后 7 或 28 天用秋水仙碱(0.1mg/kg/天)或 Cl-amidine(10mg/kg/天)治疗。通过超声心动图评估心功能,通过免疫荧光法检测 NETs。通过 2',7'-二氯二氢荧光素二乙酸酯(DCFH-DA)荧光法检测 ROS 产生。通过荧光比技术评估细胞内 Ca 浓度。
我们发现,秋水仙碱治疗可显著提高小鼠存活率(秋水仙碱组为 89.8%,对照组为 67.9%,每组 32 只;对数秩检验,p<0.05),并改善 AMI 后第 7 天(左心室射血分数(LVEF):28.0±9.2%对 12.6±3.9%,每组 8 只;p<0.001)和第 28 天(LVEF:26.2±7.2%对 14.8±6.7%,每组 8 只;p<0.001)的心脏功能。此外,秋水仙碱的给药抑制了 NETs 的形成和炎症。此外,秋水仙碱通过减少 NOX2/ROS 产生和 Ca 内流来抑制 NETs 的形成。此外,用 Cl-amidine 预防 NETs 的形成可显著减轻 AMI 引起的心脏重构。
秋水仙碱抑制 NETs 和心脏炎症,并减轻急性心肌梗死后的心脏重构。